Sclerostin antibody
Cold Chain RequiredFDA Approved, EMA Approved
Contents
Description
Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, increasing bone formation and decreasing bone resorption. It is approved for treatment of osteoporosis in postmenopausal women at high risk of fracture. The drug has potential applications in rare skeletal dysplasias involving bone formation defects.
Indications & Therapeutic Use
Osteoporosis, skeletal dysplasias with impaired bone formation
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Sclerostin antibody — GNH India
14 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Sclerostin antibody products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Sclerostin antibody
| Generic Name | sclerostin antibody |
| Brands | 1 brand available |
| Active Ingredient | romosozumab |
| Drug Class | Osteoporosis |
| Manufacturer | Amgen Inc. |
| Dosage Forms | Subcutaneous injection, 105 mg/1.17 mL |
| Medical Code | M05BX06 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT01631214 |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes